WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS

INCREASED RISK OF SERIOUS BACTERIAL, FUNGAL, VIRAL AND OPPORTUNISTIC INFECTIONS LEADING TO HOSPITALIZATION OR DEATH, INCLUDING TUBERCULOSIS (TB). DISCONTINUE TREATMENT WITH ABROCITINIB IF SERIOUS OR OPPORTUNISTIC INFECTION OCCURS. TEST FOR LATENT TB BEFORE AND DURING THERAPY; TREAT LATENT TB PRIOR TO USE. MONITOR ALL PATIENTS FOR ACTIVE TB DURING TREATMENT, EVEN PATIENTS WITH INITIAL NEGATIVE LATENT TB TEST.

HIGHER RATE OF ALL-CAUSE MORTALITY, INCLUDING SUDDEN CARDIOVASCULAR DEATH, WITH ANOTHER JAK INHIBITOR VS. TNF BLOCKERS IN RHEUMATOID ARTHRITIS (RA) PATIENTS. ABROCITINIB IS NOT APPROVED FOR USE IN RA PATIENTS.

MALIGNANCIES HAVE OCCURRED WITH ABROCITINIB. HIGHER RATE OF LYMPHOMAS AND LUNG CANCERS WITH ANOTHER JAK INHIBITOR VS. TNF BLOCKERS IN RA PATIENTS.

MACE HAS OCCURRED WITH ABROCITINIB. HIGHER RATE OF MACE (DEFINED AS CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE) WITH ANOTHER JAK INHIBITOR VS. TNF BLOCKERS IN RA PATIENTS.

THROMBOSIS HAS OCCURRED WITH ABROCITINIB. INCREASED INCIDENCE OF PULMONARY EMBOLISM, VENOUS AND ARTERIAL THROMBOSIS WITH ANOTHER JAK INHIBITOR VS. TNF BLOCKERS.